Compare WMK & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WMK | MLYS |
|---|---|---|
| Founded | 1912 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.2B |
| IPO Year | 1994 | 2023 |
| Metric | WMK | MLYS |
|---|---|---|
| Price | $70.68 | $27.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $48.67 |
| AVG Volume (30 Days) | 112.3K | ★ 909.5K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.96% | N/A |
| EPS Growth | N/A | ★ 37.43 |
| EPS | ★ 1.13 | N/A |
| Revenue | ★ $4,714,573,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $62.75 | ★ N/A |
| Revenue Growth | ★ 0.01 | N/A |
| 52 Week Low | $59.99 | $12.59 |
| 52 Week High | $79.05 | $47.65 |
| Indicator | WMK | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 52.35 | 44.27 |
| Support Level | $67.90 | $26.85 |
| Resistance Level | $73.21 | $31.12 |
| Average True Range (ATR) | 2.04 | 1.58 |
| MACD | -0.00 | -0.24 |
| Stochastic Oscillator | 33.73 | 31.23 |
Weis Markets Inc is a U.S.-based company that is principally engaged in retailing food products in Pennsylvania and surrounding states. The company's products mainly belong to the following categories: center-store goods, fresh goods, pharmacy services, fuel, and others. The center-store goods include groceries, dairy products, frozen foods, alcoholic beverages, and general merchandise items. The fresh goods include meats, seafood, floral, prepared foods, and bakery products. The center-store goods and fresh goods jointly account for the majority of the company's total revenue.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.